Estradiol Patches Noninferior to LHRH Agonists in Prostate Cancer

Standard androgen deprivation therapy for prostate cancer focuses on suppressing testosterone, but the resulting depletion of estradiol often leads to debilitating side effects that impair patient quality of life [1, 2]. While luteinizing hormone-releasing hormone agonists effectively achieve castrate levels, patients frequently experience vasomotor symptoms (hot flashes) and progressive bone mineral density loss [3, 1, 4]. Historical attempts to use oral estrogens were hampered by significant thromboembolic and cardiovascular risks, leading to a shift toward transdermal delivery methods to bypass hepatic first-pass metabolism, which is the process where the liver metabolizes a drug and increases the production of clotting factors before the medication reaches systemic circulation [5, 2]. Current clinical guidelines emphasize the need for better integration of patient-reported outcomes, which are standardized reports from patients regarding their own health status, and side-effect management in long-term hormonal therapy [6, 7]. A new study now offers evidence regarding the comparative efficacy and safety of transdermal estradiol as a primary androgen deprivation strategy.